Genmab News

To comply with applicable regulation in Denmark, product-related media releases are removed from our website within three weeks of publication. They are available upon request. Please contact us here.

May 11, 2021 at 8:43 PM CEST Capital Increase in Genmab as a Result of Employee Warrant Exercise	Download
May 10, 2021 at 9:55 AM CEST Transactions in connection with share buy-back program	Download Download
May 7, 2021 at 7:52 PM CEST Transactions with shares and linked securities in Genmab A/S made by managerial employees and their closely associated persons	Download
May 5, 2021 at 5:01 PM CEST Genmab Announces Financial Results for the First Quarter of 2021	Download
May 3, 2021 at 8:58 PM CEST Transactions with shares and linked securities in Genmab A/S made by managerial employees and their closely associated persons	Download
May 3, 2021 at 9:48 AM CEST Transactions in connection with share buy-back program	Download Download
Apr 26, 2021 at 10:44 PM CEST Genmab A/S has published its Articles of Association	Download
Apr 26, 2021 at 9:19 AM CEST Transactions in connection with share buy-back program	Download Download
Apr 20, 2021 at 12:35 PM CEST Genmab Announces Net Sales of DARZALEX® (daratumumab) for First Quarter of 2021	Download
Apr 19, 2021 at 9:52 AM CEST Transactions in connection with share buy-back program	Download Download
Apr 13, 2021 at 10:45 PM CEST Transactions with shares and linked securities in Genmab A/S made by managerial employees and their closely associated persons	Download
Apr 13, 2021 at 10:40 PM CEST Constitution of the Board of Directors in Genmab A/S and Grant of Restricted Stock Units and Warrants to Employees and a New Member of Management in Genmab	Download
Apr 13, 2021 at 3:26 PM CEST Passing of Genmab A/S’ Annual General Meeting	Download
Apr 12, 2021 at 9:55 AM CEST Transactions in connection with share buy-back program	Download Download
Apr 9, 2021 at 10:00 PM CEST Genmab and Seagen Announce U.S. FDA Filing Acceptance for Priority Review of Tisotumab Vedotin Biologics License Application for Patients with Recurrent or Metastatic Cervical Cancer	Download
Apr 6, 2021 at 9:21 AM CEST Transactions in connection with share buy-back program	Download Download
Mar 30, 2021 at 7:22 AM CEST Genmab Announces European Marketing Authorization for Kesimpta® (ofatumumab) in Relapsing Multiple Sclerosis	Download
Mar 29, 2021 at 5:20 PM CEST Genmab Files Annual Report with the U.S. Securities and Exchange Commission	Download
Mar 29, 2021 at 9:13 AM CEST Transactions in connection with share buy-back program	Download Download
Mar 22, 2021 at 10:15 AM CET Transactions in connection with share buy-back program	Download Download
Mar 15, 2021 at 9:46 AM CET Transactions in connection with share buy-back program	Download Download
Mar 9, 2021 at 10:15 AM CET Notice to Convene the Annual General Meeting of Genmab A/S	Download
Mar 8, 2021 at 9:54 AM CET Transactions in connection with share buy-back program	Download Download
Mar 7, 2021 at 12:40 PM CET Transactions with shares and linked securities in Genmab A/S made by managerial employees and their closely associated persons	Download
Mar 3, 2021 at 4:31 PM CET Genmab A/S has published its Articles of Association	Download

NEWS & EVENTS

Through timely company announcements, media releases, events and presentations, Genmab discloses and informs all our stakeholders of key events throughout the year.

Genmab News

Genmab News

Who we are

Turning insights into medicine

Innovation for the future

Genmab A/S

Genmab B.V.

Genmab US, Inc.

Genmab K.K.

You are now leaving Genmab.com to go to our collaborator’s website. If you continue, we encourage you to read the website’s privacy and cookie policy.